Evidence map›Paper›PMID 36064356›Full record

ArticleJournal of nanobiotechnology2022

Engineering cancer cell membrane-camouflaged metal complex for efficient targeting therapy of breast cancer.

Xiaoying Li, Yanzi Yu, Qi Chen, Jiabao Lin, Xueqiong Zhu, Xiaoting Liu, Lizhen He, Tianfeng Chen, Weiling He

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Recent Advancements of Nanomedicine in Breast Cancer Surgery.International journal of nanomedicine · 2024
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiaoying Li *Department of Neurology and Stroke Center, The First Affiliated Hospital, Department of Chemistry, Jinan University, Guangzhou, 510632, China.
Yanzi Yu *Department of Neurology and Stroke Center, The First Affiliated Hospital, Department of Chemistry, Jinan University, Guangzhou, 510632, China.
Qi ChenDepartment of Neurology and Stroke Center, The First Affiliated Hospital, Department of Chemistry, Jinan University, Guangzhou, 510632, China.
Jiabao LinDepartment of Neurology and Stroke Center, The First Affiliated Hospital, Department of Chemistry, Jinan University, Guangzhou, 510632, China.
Xueqiong ZhuDepartment of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xiaoting LiuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital, Center for Precision Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.
Lizhen HeDepartment of Neurology and Stroke Center, The First Affiliated Hospital, Department of Chemistry, Jinan University, Guangzhou, 510632, China. hlz6371@jnu.edu.cn.
Tianfeng ChenDepartment of Neurology and Stroke Center, The First Affiliated Hospital, Department of Chemistry, Jinan University, Guangzhou, 510632, China.
Weiling HeDepartment of Gastrointestinal Surgery, The First Affiliated Hospital, Center for Precision Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China. hewling@mail.sysu.edu.cn.
First Affiliated Hospital of Jinan University · CNSun Yat-sen University · CNWenzhou Medical University · CN

Funding

Medical Health Science and Technology Key projects of the Scientific Research Foundation of National Health, Commission of China-Zhejiang Provincial Health Commission No. WKJ-ZJ-2036National Natural Science Foundation of China 21877049National Natural Science Foundation of China 81974282National Natural Science Foundation of China 82022037
6 · The paper itself

Abstract

backgroundCancer cell membrane-camouflaged nanotechnology for metal complex can enhance its biocompatibility and extend the effective circulation time in body. The ruthenium polypyridyl complex (RuPOP) has extensive antitumor activity, but it still has disadvantages such as poor biocompatibility, lack of targeting, and being easily metabolized by the organism. Cancer cell membranes retain a large number of surface antigens and tumor adhesion molecules CD47, which can be used to camouflage the metal complex and give it tumor homing ability and high biocompatibility.

resultsTherefore, this study provides an electrostatic adsorption method, which uses the electrostatic interaction of positive and negative charges between RuPOP and cell membranes to construct a cancer cell membrane-camouflaged nano-platform (RuPOP@CM). Interestingly, RuPOP@CM maintains the expression of surface antigens and tumor adhesion molecules, which can inhibit the phagocytosis of macrophage, reduce the clearance rate of RuPOP, and increase effective circulation time, thus enhancing the accumulation in tumor sites. Besides, RuPOP@CM can enhance the activity of cellular immune response and promote the production of inflammatory cytokines including TNF-α, IL-12 and IL-6, which is of great significance in treatment of tumor. On the other hand, RuPOP@MCM can produce intracellular ROS overproduction, thereby accelerating the apoptosis and cell cycle arrest of tumor cells to play an excellent antitumor effect in vitro and in vivo.

conclusionIn brief, engineering cancer cell membrane-camouflaged metal complex is a potential strategy to improve its biocompatibility, biological safety and antitumor effects.

Indexed as

Breast NeoplasmsRutheniumAntigens, SurfaceApoptosisCell MembraneFemaleHumansAntigens, SurfaceRutheniumCamouflageCancer cell membranesCancer targeting therapyHigh biocompatibilityMetal complex

Identifiers

PMID36064356
PMCPMC9446690
OpenAlexW4294631178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.